Polianta Ltd Invests $1.57 Million in Medpace Holdings, Inc. $MEDP

Polianta Ltd purchased a new stake in Medpace Holdings, Inc. (NASDAQ:MEDP) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 2,800 shares of the company’s stock, valued at approximately $1,572,000.

Several other hedge funds have also added to or reduced their stakes in the business. Quent Capital LLC acquired a new stake in Medpace during the third quarter worth approximately $25,000. Optiver Holding B.V. acquired a new position in shares of Medpace in the third quarter valued at approximately $27,000. Quarry LP acquired a new position in shares of Medpace in the third quarter valued at approximately $35,000. Root Financial Partners LLC bought a new position in shares of Medpace during the third quarter worth approximately $38,000. Finally, Geneos Wealth Management Inc. lifted its holdings in Medpace by 64.9% during the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after purchasing an additional 37 shares during the last quarter. Institutional investors and hedge funds own 77.98% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the company. Barclays upgraded Medpace from an “underweight” rating to an “equal weight” rating and set a $500.00 price target for the company in a research note on Friday, March 6th. Robert W. Baird raised Medpace from a “neutral” rating to an “outperform” rating and set a $564.00 target price for the company in a report on Tuesday, February 10th. Zacks Research cut shares of Medpace from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 12th. Royal Bank Of Canada initiated coverage on shares of Medpace in a research note on Tuesday, March 3rd. They issued an “outperform” rating and a $522.00 price target on the stock. Finally, BMO Capital Markets reaffirmed a “market perform” rating on shares of Medpace in a research report on Wednesday, February 11th. Five analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $486.67.

Medpace Price Performance

Shares of NASDAQ MEDP opened at $460.30 on Tuesday. The stock has a market capitalization of $13.06 billion, a PE ratio of 30.08, a P/E/G ratio of 2.16 and a beta of 1.44. The business has a fifty day moving average price of $491.06 and a two-hundred day moving average price of $537.58. Medpace Holdings, Inc. has a fifty-two week low of $250.05 and a fifty-two week high of $628.92.

Medpace (NASDAQ:MEDP) last released its earnings results on Monday, February 9th. The company reported $4.67 earnings per share for the quarter, beating analysts’ consensus estimates of $4.18 by $0.49. Medpace had a return on equity of 118.82% and a net margin of 17.83%.The firm had revenue of $708.45 million during the quarter, compared to the consensus estimate of $689.53 million. During the same period in the prior year, the company posted $3.67 EPS. The company’s revenue was up 32.0% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. On average, equities analysts expect that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Insider Transactions at Medpace

In other news, President Jesse J. Geiger sold 31,707 shares of the business’s stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $455.30, for a total value of $14,436,197.10. Following the completion of the transaction, the president directly owned 15,000 shares in the company, valued at approximately $6,829,500. The trade was a 67.88% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 20.30% of the stock is owned by insiders.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.